Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Other Non-Cash Items · Q3 FY2026 · quarter ended Sep 2026

Other non-cash items declines year over year

Q3 FY2026 other non-cash items of $4.31M (cash outflow) fell 89.6% year over year, behind the -41.1% change in trailing-twelve-month other non-cash items. Sequentially, it fell 88.7% from the prior quarter.

Context

  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.6% toward the trailing-twelve-month pace of -41.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$4.31M-88.7% QoQ
Last fiscal yearDec 2025
-$55.73M-640.6% YoY
LTMSep 2026
-$33.58M-41.1% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.6%——
1 year-640.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
(55.73M) USD
Year-over-year change
-640.6%

Other Non-Cash Items vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -41.1% is the 6th highest of 8, against a peer median of +42.2%.
  • Other non-cash items amounts to 37.1% of revenue for SYRE, versus a peer median of 56.9%.
SYRE Competitors
Other Non-Cash Items for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABVXAbivax S.A.FY2025€162.57M EUR+28274.2%+157.8%—
ANABAnaptysBio, Inc.LTM Mar 2026$78.61M USD+42.2%-12.8%33.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$33.58M USD-41.1%—37.1%
IFRXInflaRx N.V.LTM Mar 2026€6.04M EUR+205.4%—20599.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$4.76M USD-94.7%-21.2%56.9%
ARDXArdelyx, Inc.LTM Mar 2026$4.38M USD-226.7%—1.0%
UPBUpstream Bio, Inc.LTM Mar 2026$2.14M USD-13.3%+55.6%64.5%
IMUXImmunic, Inc.LTM Mar 2026$595K USD+331.5%-76.4%—
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —+42.2%-12.8%56.9%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.